BRIDGEWATER, N.J., June 6, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that Rob Stewart, President and Chief Executive Officer, and Bryan Reasons, Senior Vice President and Chief Financial Officer, will present at the Goldman Sachs 39th Annual Global Healthcare Conference in Rancho Palos Verdes, CA, on Wednesday, June 13, 2018 at 11:20 a.m. Pacific Time (2:20 p.m. Eastern Time).

(PRNewsfoto/Amneal Pharmaceuticals, Inc.)

To access a live webcast of the presentation, visit Amneal's Investor Relations Web site at https://investors.amneal.com/Investor-Relations. The webcast can also be accessed at the following URL: https://cc.talkpoint.com/gold006/061218a_as/?entity=80_H87J1SO.

An archived version will be available approximately one hour after the live presentation ends and can be accessed at the same locations for 90 days.

About Amneal
Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is an integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company has approximately 6,500 employees in its operations in North America, Asia, and Europe, working together to bring high-quality medicines to patients primarily within the United States.

Amneal is one of the largest and fastest growing generic pharmaceutical manufacturers in the United States, with an expanding portfolio of generic products to include complex dosage forms in a broad range of therapeutic areas. The Company markets a portfolio of branded pharmaceutical products through its Impax Specialty Pharma division focused principally on central nervous system disorders and parasitic infections. For more information, visit www.amneal.com.  

Contact: 
Mark Donohue
Investor Relations and Corporate Communications  
(215) 558-4526
www.amneal.com                

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/amneal-to-present-at-the-goldman-sachs-39th-annual-global-healthcare-conference-300660745.html

SOURCE Amneal Pharmaceuticals, Inc.